We discover, develop and deliver innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world. Our ultimate goal for our patients is – Vision For Life.
A new era of medicine
Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of age-related macular degeneration (AMD) and gene therapy as a mode of sustained treatment delivery.
Our achievements would not be possible without the outstanding team that make up Gyroscope.
We are developing gene therapies beyond rare disease.
At Gyrocope, science is at the core of everything we do.
Developing surgical devices and procedures designed to deliver one-time therapies to the subretinal space.
Age-related macular degeneration is the leading cause of irreversible blindness in the elderly. Today there is no effective treatment for the atrophic form of the disease.
Our global management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at multiple innovative biotech and pharmaceutical companies.
Through our delivery system we also have significant surgical device development and surgeon training capabilities.
our approach to
With world-class expertise in gene therapy and drug development, particularly in the field of ophthalmology Gyroscope is committed to partnering with academic partners, pharmaceutical and biotech companies to accelerate clinical research to develop cutting-edge gene therapies and surgical delivery devices to tackle some of the toughest eye diseases that steal the vision of millions of people around the world.
OUR PROMISE TO PATIENTS
– is big
Gyroscope was created to bring the right people and resources together to fundamentally change the lives of patients suffering from retinal diseases.
We know that our people, with their passion for patients, will drive to deliver on this promise.
Gyroscope are continuing to attend events in 2020
During 2020 we will be attending both virtual and in person conferences and events.
Please keep up to date by checking back regularly.
Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).